A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00354653|
Recruitment Status : Unknown
Verified July 2007 by GlaxoSmithKline.
Recruitment status was: Active, not recruiting
First Posted : July 20, 2006
Last Update Posted : July 25, 2007
|Condition or disease||Intervention/treatment||Phase|
|Chronic Hepatitis B||Drug: LAMIVUDINE||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||AN OPEN STUDY OF LAMIVUDINE TREATMENT IN ADULT HBeAg NEGATIVE (Presumed Pre-Core Mutant) CHRONIC HEPATITIS B PATIENTS IN IRAN.|
|Study Start Date :||February 2002|
- Complete virologic response at Month 24 which is normalisation of alanine aminotransferase (ALT) and disappearance of HBV DNA by NAXCOR(brand name of a virus assay kit)
- Partial response, histological improvement (at 24 months). Sustained complete response, sustained partial response at 30 months.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00354653
|Iran, Islamic Republic of|
|GSK Clinical Trials Call Center|
|Tehran, Iran, Islamic Republic of, 1919954186|
|Study Director:||GSK Clinical Trials, MD||GlaxoSmithKline|